Troxacitabine: Difference between revisions
m Protected "Troxacitabine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
'''Troxacitabine''' (brand name '''Troxatyl''') is a [[nucleoside analogue]] with anticancer activity. Its use is being studied in patients with refractory [[lymphoproliferative disease]]s. | '''Troxacitabine''' (brand name '''Troxatyl''') is a [[nucleoside analogue]] with anticancer activity. Its use is being studied in patients with refractory [[lymphoproliferative disease]]s. | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 17:08, 20 August 2012
WikiDoc Resources for Troxacitabine |
Articles |
---|
Most recent articles on Troxacitabine Most cited articles on Troxacitabine |
Media |
Powerpoint slides on Troxacitabine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Troxacitabine at Clinical Trials.gov Trial results on Troxacitabine Clinical Trials on Troxacitabine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Troxacitabine NICE Guidance on Troxacitabine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Troxacitabine Discussion groups on Troxacitabine Patient Handouts on Troxacitabine Directions to Hospitals Treating Troxacitabine Risk calculators and risk factors for Troxacitabine
|
Healthcare Provider Resources |
Causes & Risk Factors for Troxacitabine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.